This study aims to evaluate the effectiveness of a polymer-based, paclitaxel-eluting stent compared to bare-metal stents in reducing restenosis.
Compared polymer-based paclitaxel-eluting stents with bare-metal stents
Followed patients for nine months
Analyzed rates of clinical and angiographic restenosis.
The paclitaxel-eluting stent significantly reduced clinical restenosis rates compared to bare-metal stents.
Angiographic restenosis rates were markedly lower with the polymer-based stent at nine months.
Abstract
As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.